Prospective study of everolimus with calcineurin inhibitor-free immunosuppression in maintenance heart transplant patients: Results at 2 years

Transplantation

Volumn 91, Issue 10, 2011, Pages 1159-1165

  Engelen, Markus A ^a   Amler, Susanne ^b   Welp, Henryk ^a   Vahlhaus, Christian ^a   Gunia, Stefan ^a   Sindermann, Juergen R ^b   Rothenburger, Markus ^b   Stypmann, Jörg ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Certican; CNI free; Conversion; Everolimus; Heart transplantation; Renal function

Indexed keywords

CALCINEURIN INHIBITOR; CYCLOSPORIN A; EVEROLIMUS; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID;

ACNE; ADULT; ANEMIA; ARTICLE; CARDIAC ALLOGRAFT VASCULOPATHY; CARDIAC GRAFT REJECTION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE CLEARANCE; DIASTOLIC BLOOD PRESSURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOCARDITIS; FEMALE; GINGIVA HYPERPLASIA; HEART FUNCTION; HEART TRANSPLANTATION; HIRSUTISM; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTIOUS PNEUMONIA; INFLUENZA; INTERSTITIAL PNEUMONIA; KIDNEY DISEASE; KIDNEY FUNCTION; LEUKOPENIA; LIPOMETABOLIC DISORDER; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MORTALITY; MUSCLE CRAMP; PERIPHERAL EDEMA; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RHEUMATIC DISEASE; SIDE EFFECT; SKIN DISEASE; SYSTOLIC BLOOD PRESSURE; TREMOR; TRIACYLGLYCEROL BLOOD LEVEL; TRICUSPID VALVE ENDOCARDITIS; WEIGHT REDUCTION;

BIOLOGICAL MARKERS; BLOOD PRESSURE; CALCINEURIN; CREATININE; CYCLOSPORINE; DRUG ADMINISTRATION SCHEDULE; DRUG SUBSTITUTION; GERMANY; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KAPLAN-MEIER ESTIMATE; KIDNEY; KIDNEY DISEASES; LIPIDS; PROSPECTIVE STUDIES; SIROLIMUS; TIME FACTORS; TREATMENT OUTCOME;

EID: 79955601688     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31821774bd     Document Type: Article

References (28)

1. Keogh A. Calcineurin inhibitors in heart transplantation. J Heart Lung Transplant 2004; 23(suppl 5): S202.
2. Organ Procurement and Transplantation Network reports 1996-2001. Available at: http://www.optn.org. Accessed April 5, 2011.
3. Lindenfeld J, Miller GG, Shakar SF, et al. Drug therapy in the heart transplant recipient: Part II: Immunosuppressive drugs. Circulation 2004; 110: 3858.
4. Chapman TM, Perry CM. Everolimus. Drugs 2004; 64: 861; discussion 873.
5. Eisen HJ, Tuzcu EM, Dorent R, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003; 349: 847.
6. Leet AS, Bergin PJ, Richardson M, et al. Outcomes following de novo CNI-free immunosuppression after heart transplantation: A singlecenter experience. Am J Transplant 2009; 9: 140.
7. Kobashigawa J, Miller L, Renlund D, et al. A randomized activecontrolled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators. Transplantation 1998; 66: 507.
8. Lyster H, Panicker G, Leaver N, et al. Initial experience with sirolimus and mycophenolate mofetil for renal rescue from cyclosporine nephrotoxicity after heart transplantation. Transplant Proc 2004; 36: 3167.
9. Groetzner J, Kaczmarek I, Meiser B, et al. Sirolimus and mycophenolate mofetil as calcineurin inhibitor-free immunosuppression in a cardiac transplant patient with chronic renal failure. J Heart Lung Transplant 2004; 23: 770.
10. Valantine H. Prevention of cardiac allograft vasculopathy with Certican (everolimus): The Stanford University experience within the Certican Phase III clinical trial. J Heart Lung Transplant 2005; 24(suppl 4): S191.
11. Lehmkuhl H, Hetzer R. Clinical experience with Certican (everolimus) in de novo heart transplant patients at the Deutsches Herzzentrum Berlin. J Heart Lung Transplant 2005; 24(suppl 4): S201.
12. Ross H, Flugfelder P, Haddad H, et al. Cyclosporine reduction in the presence of everolimus: 3-month data from a Canadian pilot study of maintenance cardiac allograft recipients. J Heart Lung Transplant 2008; 27: 197.
13. Zuckermann A. Clinical experience with Certican (everolimus) in maintenance heart transplant patients at the Medical University of Vienna. J Heart Lung Transplant 2005; 24(suppl 4): S206.
14. Rothenburger M, Teerling E, Bruch C, et al. Calcineurin inhibitor-free immunosuppression using everolimus (Certican) in maintenance heart transplant recipients: 6 months' follow-up. J Heart Lung Transplant 2007; 26: 250.
15. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31.
16. Lebranchu Y, Thierry A, Toupance O, et al. Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: CONCEPT study. Am J Transplant 2009; 9: 1115.
17. Weir M, Mulgaonkar S, Pearson T, et al. Mycophenolate mofetil/sirolimus maintenance therapy after calcineurin inhibitor withdrawal in renal transplant recipients: 2-year outcomes of the Spare-the-Nephron (STN) trial. Am J Transplant 2009; 9: 200 (abstract 33).
18. Budde K, Becker T, Sommerer C, et al. Analysis of renal function in everolimus/enteric-coated mycophenolate sodium treated de novo renal transplant recipients after calcineurin inhibitor withdrawal: The Zeus Study. Am J Transplant 2009; 9: 259 (abstract 237).
19. Gleissner CA, Doesch A, Ehlermann P, et al. Cyclosporine withdrawal improves renal function in heart transplant patients on reduced-dose cyclosporine therapy. Am J Transplant 2006; 6: 2750.
20. Schena FP, Pascoe MD, Alberu J, et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 2009; 87: 233.
21. Moro J, Almenar L, Martínez-Dolz L, et al. mTOR inhibitors and their secondary effects in cardiac transplant recipients: A descriptive study. Transplant Proc 2007; 39: 2365.
22. Vítko S, Margreiter R, Weimar W, et al. Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 2005; 5: 2521.
23. Ayala M, Morales J, Fierro A, et al. Metabolic changes following conversion from an anticalcineurin-based therapy to an everolimus- based one: A single-center experience. Transplant Proc 2008; 40: 3265.
24. Tenderich G, Fuchs U, Zittermann A, et al. Comparison of sirolimus and everolimus in their effects on blood lipid profiles and haematological parameters in heart transplant recipients. Clin Transplant 2007; 21: 536.
25. Moro JA, Almenar L, Martínez-Dolz L, et al. Tolerance profile of the proliferation signal inhibitors everolimus and sirolimus in heart transplantation. Transplant Proc 2008; 40: 3034.
26. Rothenburger M, Stypmann J, Welp H, et al. Calcineurin inhibitor-free immunosuppression using everolimus in long term heart transplant recipients-Procedures of switching protocols and side effects. J Heart Lung Transplant 2006; 25: S166 (abstract 356).
27. Viganò M, Tuzcu M, Benza R, et al. Prevention of acute rejection and allograft vasculopathy by everolimus in cardiac transplants recipients: A 24-month analysis. J Heart Lung Transplant 2007; 26: 584.
28. Brignol N, McMahon LM, Luo S, et al. High-throughput semiautomated 96-well liquid/liquid extraction and liquid chromatography/ mass spectrometric analysis of everolimus (RAD 001) and cyclosporin A (CsA) in whole blood. Rapid Commun Mass Spectrom 2001; 15: 898.